8 October 2018 - NICE is recommending Mylotarg for previously untreated, de novo, CD33-positive acute myeloid leukaemia in combination with chemotherapy.

The Final Appraisal Determination now backs use of the drug in combination with daunorubicin and cytarabine for untreated CD33-positive AML (except acute promyelocytic leukaemia) in people 15 years and over with favourable, intermediate or unknown cytogenetics (because the test was unsuccessful).

Earlier draft guidelines only recommended Mylotarg (gemtuzumab ozogamicin) for patients with favourable or unknown cytogenetics, but not for those with intermediate cytogenetics, which would have excluded around 65 percent of the eligible patient population.

Read Pharma Times article